Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 172, Issue 8, 2005, Pages 1008-1012

  Saiman, Lisa ^a   Mayer Hamblett, Nicole ^b   Campbell, Preston ^b   Marshall, Bruce C ^b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NONE

Author keywords

Antibiotic; Azithromycin; Cystic fibrosis; Macrolide; Pseudomonas aeruginosa

Indexed keywords

AZITHROMYCIN; DORNASE ALFA; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC HETEROGENEITY; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; DRUG MONITORING; FORCED EXPIRATORY VOLUME; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HOSPITALIZATION; HUMANS; PNEUMONIA, BACTERIAL; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PSEUDOMONAS INFECTIONS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TOBRAMYCIN; TREATMENT OUTCOME; UNITED STATES;

EID: 26944446140     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200502-218OC     Document Type: Article

References (8)

1. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled cross-over trial. Lancet 2002;360:978-984.
2. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57:212-216.
3. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290:1749-1756.
4. Saiman L, for the Macrolide Study Group. What have we learned from further analysis of the US macrolide trial: subgroup analysis of the azithromycin trial? Pediatr Pulmonol 2003;36(Suppl. 25):165-167.
5. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-734.
6. Southern K, Barker P, Sous A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2004;2:CD002203.
7. Tsai WC, Rodriguez ML, Young KS, Deng JC, Thannickal VJ, Tateda K, Hershenson MB, Standiford TJ. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med 2004;170:1331-1339.
8. Saiman L. The use of macrolide antibiotics in patients with cystic fibrosis. Curr Opin Pulm Med 2004;10:515-523.